Major HIV vaccine candidates
DOI:
https://doi.org/10.12775/JEHS.2023.34.01.008Keywords
Human immunodeficiency virus HIV, acquired immunodeficiency syndrome (AIDS), vaccineAbstract
Introduction and objective: Human immunodeficiency virus (HIV) is a virus, which is responsible for an acquired immunodeficiency syndrome (AIDS). This pathogen is widespread worldwide causing a pandemic that has been going on for decades. Researches around the world are trying to end this situation and it seems that the greatest hope lies in finding an effective vaccine. It is important due to the fact that AIDS and its consequences are responsible even nowadays for death of many people infected around the world. The aim of this study was to provide the most important information about major HIV vaccine trials and efficacy of vaccine candidates.
Materials and methods: For the purposes of writing this article, the available literature was reviewed. The database of medical publications – Pubmed datebase and other publicaly available books, database and online sites was searched, with the use of keywords such as HIV, HIV vaccine, HIV epidemiology.
State of knowledge: According to review studies HIV vaccine trials has been going for 4 decades. Over 250 trials has been conducted since then, but unfortunately, none of them resulted in effective vaccine. The difficulties of this task are mainly connected with the nature of HIV virus. To date, one study has shown some effectiveness, but not enough to claim success. Other studies are ongoing around the world and more are planned.
Conclusions: Developing an effective HIV vaccine is the clue to solving the problem, which is new HIV infections. Further researches, further research funding and international cooperation are needed to end this pandemic.
References
Meyer H, Ehmann R, Smith GL, Smallpox in the Post-Eradication Era. Viruses 2020, 12(2):138.
Platto S, Wang Y, Zhou J, Carafoli E. History of the COVID-19 pandemic: Origin, explosion, worldwide spreading. Biochem Biophys Res Commun. 2021, 538:14-23.
https://covid19.who.int/ (22.04.2023)
Johnston MI, Scarlatti G, Pitisutthithum P, Bekker L-G. HIV vaccines: progress and promise. J Inter Aids Soc. 2021, 24(S7):225828.
Hannah S, Chinyenze K, Shattock R,Yola N, Warren M. HIV vaccines in 2022: where to from here? J Inter Aids Soc. 2022, 25:e25923.
https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf (20.04.2023)
Hargrave A, Mustafa AS, Hanif A, Tunio JH, Hanif SNM. Current Status of HIV-1 Vaccines. Vaccines, 2021, 9(9):1026.
Huynh K; Gulick PG. HIV Prevention. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
Wang H-B, Mo Q-H, Yang Z. HIV Vaccine Research: The Challenge and the Way Forward. J Immunol Res. 2015, 2015:503978.
Kim J, Vasan S, Kim JH, Ake JA. Current approaches to HIV vaccine development: a narrative review. J Inter Aids Soc. 2021, 24(S7):e25793.
Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005, 191(5):654-65.
Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006, 194(12):1661-71.
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM. Chodakewitz JA, Corey L, Robertson MN. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat Ch, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009, 361(23):2209-20.
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(23)00030-9/fulltext (26.04.2023)
https://www.jnj.com/janssen-and-global-partners-to-discontinue-phase-3-mosaico-hiv-vaccine-clinical-trial (26.04.2023)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Wojciech Zdziennicki, Patryk Zimnicki, Marta Lato, Konrad Iberszer, Maria Litwiniuk, Marcin Zaniuk, Kamil Hurkała, Dominika Antonik, Barbara Denys, Karolina Góra
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 246
Number of citations: 0
